Search Results

You are looking at 1 - 10 of 32 items for :

  • endogenous Cushing’s syndrome x
Clear All
Open access

Jingya Zhou, Meng Zhang, Lin Lu, Xiaopeng Guo, Lu Gao, Weigang Yan, Haiyu Pang, Yi Wang and Bing Xing

Introduction Endogenous Cushing’s syndrome (CS) comprises signs and symptoms caused by pathological hypercortisolism, which seriously affects the metabolic and endocrine systems. Endogenous CS is divided between adrenocorticotropic hormone

Open access

Carla Scaroni, Nora M Albiger, Serena Palmieri, Davide Iacuaniello, Chiara Graziadio, Luca Damiani, Marialuisa Zilio, Antonio Stigliano, Annamaria Colao, Rosario Pivonello and the Altogether to Beat Cushing’s Syndrome (ABC) study group

( 2 ). Under such conditions, there may be some clinical signs of hypercortisolism, which may be temporary or more persistent, giving rise to what is called pseudo-Cushing’s syndrome (PCS). The differential diagnosis of PCS and Cushing’s syndrome (CS

Open access

Boni Xiang, Ran Tao, Xinhua Liu, Xiaoming Zhu, Min He, Zengyi Ma, Yehong Yang, Zhaoyun Zhang, Yiming Li, Zhenwei Yao, Yongfei Wang and Hongying Ye

Introduction Cushing’s syndrome (CS) comprises diverse manifestations resulting from chronic exposure to excess glucocorticoids. The incidence is 0.2–5.0 per million people per year. Approximately 80% of endogenous CS is adrenocorticotrophin

Open access

Alberto Giacinto Ambrogio, Massimiliano Andrioli, Martina De Martin, Francesco Cavagnini and Francesca Pecori Giraldi

parameter for percent ACTH increase was far lower 0.3926 (95% C.I. 0.243; 0.506). Discussion The management of patients with Cushing’s disease requires considerable expertise. First, diagnosis of endogenous cortisol excess is by no means

Open access

Bjørn O Åsvold, Valdemar Grill, Ketil Thorstensen and Marit R Bjørgaas

Introduction The 1 mg overnight dexamethasone suppression test (DST) is a common initial test for endogenous Cushing's syndrome (1) . The principle of the test is that dexamethasone will suppress ACTH and cortisol secretion in healthy individuals

Open access

Emmanuelle Motte, Anya Rothenbuhler, Stephan Gaillard, Najiba Lahlou, Cécile Teinturier, Régis Coutant and Agnès Linglart

Magiakou MA Mastorakos G Chrousos GP. Final stature in patients with endogenous Cushing’s syndrome . Journal of Clinical Endocrinology and Metabolism 1994 79 1082 – 1085 . ( https://doi.org/10.1210/jcem.79.4.7962277 ) 37 Magiakou MA Mastorakos G

Open access

Prachi Bansal, Anurag Lila, Manjunath Goroshi, Swati Jadhav, Nilesh Lomte, Kunal Thakkar, Atul Goel, Abhidha Shah, Shilpa Sankhe, Naina Goel, Neelam Jaguste, Tushar Bandgar and Nalini Shah

.1111/cen.12300 ) 10.1111/cen.12300 23895112 7 Nieman LK Biller BM Findling JW Murad MH Newell-Price J Savage MO Tabarin A. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline . Journal of

Open access

Filippo Ceccato, Diego Cecchin, Michele Gregianin, Giacomo Ricci, Cristina Campi, Filippo Crimì, Marta Bergamo, Annibale Versari, Carmelo Lacognata, Federico Rea, Mattia Barbot and Carla Scaroni

Introduction Cushing’s syndrome (CS), characterized by excessive endogenous cortisol secretion, is in most cases ACTH-dependent. Corticotropin (ACTH) secretion arises from a pituitary adenoma (Cushing’s disease) or, less frequently, from a non

Open access

Nidan Qiao

S. Mortality in Cushing’s syndrome: data from 386 patients from a single tertiary referral center . European Journal of Endocrinology 2013 169 621 – 627 . ( https://doi.org/10.1530/EJE-13-0320 ) 23939921 10.1530/EJE-13-0320 9 van Haalen

Open access

Hershel Raff and Hariprasad Trivedi

evaluate the possibility of endogenous Cushing's syndrome in patients with chronic kidney failure and we have been unable to provide a definitive answer based on previous studies (1, 2) . In patients with ESRD on chronic dialysis therapy, the mortality